We came across a bullish thesis on AbbVie Inc. (ABBV) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $171.56 which represents a decrease of $-2.14 or -1.23% from the prior close of $173.7. The stock opened at $172.88 and touched a ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

There are several Canadian companies that offer funds that invest in U.S. stocks with a covered call strategy. One is ...

Invest in Franklin Templeton mutual funds like FNRAX, FQTEX and FVHIX for growth and stability in your portfolio.

FCPI's portfolio shows resilience in consumer staples and healthcare, but faces uncertainty in energy and basic materials ...

Investors would want to prepare for rotating out of the seven - Apple (AAPL), Microsoft (MSFT), Alphabet (GOOGL), Amazon (AMZN), Nvidia (NVDA), Meta (META), and Tesla (TSLA). In exchange, they ...

While pediatric atopic dermatitis cases rose globally between 2000 and 2021, the prevalence rate dropped, showing important ...

Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical ...

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

Japanese drugmaker Sumitomo Pharma Company has concluded a co-promotion collaboration partner agreement with US healthcare ...